Zacks Investment Research Downgrades Seres Therapeutics, Inc. (NASDAQ:MCRB) to Hold

Zacks Investment Research downgraded shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) from a buy rating to a hold rating in a research report released on Tuesday.

According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

Several other equities research analysts have also commented on MCRB. Canaccord Genuity set a $20.00 price objective on Seres Therapeutics and gave the stock a buy rating in a research report on Thursday, August 3rd. BidaskClub upgraded Seres Therapeutics from a hold rating to a buy rating in a research report on Tuesday, July 25th. HC Wainwright restated a buy rating and issued a $19.00 price objective (up previously from $15.00) on shares of Seres Therapeutics in a research report on Friday, August 4th. ValuEngine upgraded Seres Therapeutics from a sell rating to a hold rating in a research report on Tuesday, August 1st. Finally, Cantor Fitzgerald set a $16.00 price objective on Seres Therapeutics and gave the stock a buy rating in a research report on Thursday, May 4th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company has an average rating of Buy and a consensus price target of $17.00.

Seres Therapeutics (NASDAQ MCRB) opened at 13.77 on Tuesday. The company has a 50 day moving average of $12.55 and a 200-day moving average of $10.69. The stock’s market cap is $557.85 million. Seres Therapeutics has a 12-month low of $8.85 and a 12-month high of $15.09.

Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.69) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.59) by $0.10. Seres Therapeutics had a negative return on equity of 80.21% and a negative net margin of 441.38%. The company had revenue of $3 million during the quarter, compared to analysts’ expectations of $3 million. During the same quarter in the prior year, the company posted ($0.70) EPS. The company’s revenue for the quarter was up .0% on a year-over-year basis. Equities analysts forecast that Seres Therapeutics will post ($2.48) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/08/12/zacks-investment-research-downgrades-seres-therapeutics-inc-nasdaqmcrb-to-hold.html.

Several hedge funds and other institutional investors have recently made changes to their positions in MCRB. Dimensional Fund Advisors LP raised its position in shares of Seres Therapeutics by 45.7% in the second quarter. Dimensional Fund Advisors LP now owns 36,600 shares of the biotechnology company’s stock worth $414,000 after buying an additional 11,488 shares during the period. Citadel Advisors LLC raised its position in shares of Seres Therapeutics by 94.6% in the second quarter. Citadel Advisors LLC now owns 40,212 shares of the biotechnology company’s stock worth $455,000 after buying an additional 19,550 shares during the period. Parametric Portfolio Associates LLC raised its position in shares of Seres Therapeutics by 2.7% in the second quarter. Parametric Portfolio Associates LLC now owns 21,915 shares of the biotechnology company’s stock worth $248,000 after buying an additional 580 shares during the period. Advisor Group Inc. raised its position in shares of Seres Therapeutics by 100.7% in the second quarter. Advisor Group Inc. now owns 14,050 shares of the biotechnology company’s stock worth $160,000 after buying an additional 7,050 shares during the period. Finally, ARK Investment Management LLC raised its position in shares of Seres Therapeutics by 21.5% in the second quarter. ARK Investment Management LLC now owns 765,191 shares of the biotechnology company’s stock worth $8,647,000 after buying an additional 135,276 shares during the period. Hedge funds and other institutional investors own 75.31% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Get a free copy of the Zacks research report on Seres Therapeutics (MCRB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

What are top analysts saying about Seres Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Seres Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit